Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stent standards

This article was originally published in The Gray Sheet

Executive Summary

FDA could adopt up to five new testing standards for vascular stents in early 2003 if the ASTM International Technical Committee on Medical and Surgical Materials and Devices passes the proposed standards in a reballoting scheduled for March and the entire organization approves them in November. The proposed standards include a guide for measuring securement of a stent mounted on a delivery system, a test method for generating stent and stent-graft flexibility curves, a test method for in vitro pulsatile fatigue, a test method for radiopacity and a guide for finite element analysis of radially loaded stents. The committee decided at their September 2001 meeting that drug-eluting stents are too early in development to warrant formal standards in the foreseeable future. Instead, FDA recommends that developers refer to the 1draft consensus report on recommended standards for preclinical studies and evaluation of drug-eluting stents, developed by several leading researchers and clinicians. The ASTM committee will continue to review comments on the draft...

You may also be interested in...



FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel